Results 51 to 60 of about 4,681,502 (208)

Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance [PDF]

open access: yes, 2004
Drug-resistant tuberculosis can be transmitted (primary) or develop during the course of treatment (secondary). We investigated risk factors for each type of resistance.
Glynn, JR   +5 more
core   +1 more source

A mitochondrial lipid metabolism–related gene signature predicts prognosis and immune landscape in colorectal cancer

open access: yesFrontiers in Immunology
BackgroundColorectal cancer (CRC) is a highly aggressive gastrointestinal malignancy with significant global health consequences. While mitochondrial lipid metabolism genes are known to influence CRC progression, their prognostic relevance remains ...
Hou Wang   +5 more
doaj   +1 more source

GENO-TYPING OF M. TUBERCULOSIS ISOLATES WITH MULTIPLE DRUG RESISTANCE CIRCULATING IN THE SOUTHERN REGIONS OF KAZAKHSTAN

open access: yesТуберкулез и болезни лёгких, 2015
Kazakhstan has one of the highest incidence of multiple drug resistant tuberculosis in the world. The goal is to describe isolated of M. tuberculosis circulating in the Southern regions of Kazakhstan basing on MIRU-VNTR-profile and spectrum of gene ...
P. V. Tarlykov   +4 more
doaj  

A community effort to assess and improve drug sensitivity prediction algorithms

open access: yes, 2014
Predicting the best treatment strategy from genomic information is a core goal of precision medicine. Here we focus on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer ...
이준학, JamesCCostello
core  

Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery.

open access: yes, 2020
Approximately one third of newly discovered drug molecules show insufficient water solubility and therefore low oral bio-availability. Self-nano-emulsifying drug-delivery systems (SNEDDSs) are one of the emerging strategies developed to tackle the issues
Beloqui Garcia, Ana   +7 more
core   +1 more source

Drug targeting to tumors using HPMA copolymers [PDF]

open access: yes, 2009
Copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) are prototypic and well-characterized polymeric drug carriers that have been broadly implemented in the delivery of anticancer agents.
Dep Farmaceutische wetenschappen   +2 more
core   +1 more source

Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies

open access: yesClinical and Translational Medicine
Background Despite guideline‐directed therapies, most patients with advanced oesophageal squamous cell carcinoma (ESCC) derive limited benefit and are unable to tolerate iterative treatment modifications.
Chen‐Ye Shao   +13 more
doaj   +1 more source

A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity

open access: yesFrontiers in Genetics, 2015
Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, among other cancer hallmarks. High throughput omics techniques are used
Ted G Laderas   +3 more
doaj   +1 more source

Novel insights in the fecal egg count reduction test for monitoring drug efficacy against soil-transmitted helminths in large-scale treatment programs [PDF]

open access: yes, 2011
Background The fecal egg count reduction test (FECRT) is recommended to monitor drug efficacy against soil-transmitted helminths (STHs) in public health.
Robert J. Dobson   +20 more
core   +1 more source

Brief strategic family therapy for adolescent drug abuse. [PDF]

open access: yes, 2003
To ensure that treatment providers apply the most current scientifically supported approaches to their patients, NIDA has supported the development of the "Therapy Manuals for Drug Addiction" series.

core  

Home - About - Disclaimer - Privacy